Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.~* A male or female between, and including, 6 and 35 months of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Subjects in stable health as determined by investigator's clinical examination and assessment of subject's medical history.~* Subjects are eligible regardless of history of administration of influenza vaccine in a previous season.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. Routine registered childhood vaccinations are permitted.~* Child in care.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.~* Prior receipt of any seasonal or pandemic influenza vaccine within six months preceding the first dose of study vaccine, or planned use during the study period.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* History of Guillain-Barré syndrome within six weeks of receipt of prior influenza vaccine.~* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.~* Acute disease and/or fever at the time of enrollment.~  * Fever is defined as temperature ≥ 38.0°C/100.4°F by any method.~ * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.~* Any significant disorder of coagulation or treatment with warfarin derivatives or heparin.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- FluLaval Quadrivalent Group (Type: EXPERIMENTAL): Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
- Fluzone Group (Type: ACTIVE_COMPARATOR): Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete